received by the International Bureau on 05 April 2017 (05.04.2017)

1. A compound having (Formula II) or

(Formula III), including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof; wherein each of Rl, R2, R3, and_R4, independently include any chemical moiety that permits the resulting compound to inhibit DYRK1 A activity.

2. The compound of Claim 1, wherein each Rl, R2, R3, and_R4, independently include any chemical moiety that permits the resulting compound to inhibit one or more of:

DYRK1A related PI3K/Akt signaling;

DYRK1A related tau phosphorylation;

DYRK1 A related NFAT phosphorylation;

DYRK1A related AS 1/J K1 pathway activation;

DYRK1 A related p53 phosphorylation;

DYRK 1 A related Amph 1 phosphorylation;

DYRK1A related Dynamin 1 phosphorylation;

DYRK 1 A related Synaptojanin phosphorylation;

DYRK 1 A related presenillin 1 (the catalytic sub-unit of γ-secretase) activity;

DYRK 1 A related Amyloid precursor protein phosphorylation;

DYRK 1 A related SIRT1 activation; and

DYRK IB related activity.

3. (Cancelled)

90

91

92

5. The compound of Claim 4, wherein R5 is selected from hydrogen, alkoxy, alkylsulfonyl, cyano, carboxy, ester, amido, substituted amido, sulfonamide, substituted sulfonamide, methylenedioxy, heterocyclyl alkyl, heterocyclyl, and heterocyclyl alkyl amido, a lipophilic

93

94

6. The compound of Claim 4, wherein R6 is selected from hydrogen, C1 -C4 alkyl, heterocyclyl alkyl, heteroaryl alkyl, aryl alkyl, aryl, heterocyclyl, and heteroaryl.

7. The compound of Claim 4, wherein R7 is selected from hydrogen, alkoxy, alkylsulfonyl, cyano, carboxy, ester, amido, substituted amido, sulfonamide, substituted sulfonamide, methylenedioxy, heterocyclyl alkyl, heterocyclyl, and heterocyclyl alkyl amido, a lipophilic

moiety comprising ether functionality, methyl, ethyl, (CH₂)3,

8. The compound of Claim 1 , wherein each of R2 and R3 is independently selected from

hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl,

95

96

10. (Cancelled)

11. (Cancelled)

12. The compound of Claim 1 , wherein said compound is selected from the following compounds:

98

99

100

101

13. A pharmaceutical composition comprising a compound of Claim 1.

14. A method of treating, ameliorating, or preventing a disorder related to DYRKIA activity in a patient comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of Claim 13.

1 . The method of Claim 14, wherein said disorder related to DYRKIA activity is

Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, an autoimmune disease, an inflammatoiy disorder (e.g., airway inflammation), or cancer (e.g., glioblastoma).

102

16. The method of Claim 15, wherein said patient is a human patient.

17. The method of Claim 15, further comprising administering to said patient one or more agents for treating Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune disease, an inflammatory disorder (e.g., airway inflammation), or cancer (e.g., glioblastoma).

18. A kit comprising a compound of Claim 1 and instructions for administering said compound to a patient having a disorder related to DYRK1 activity.

19. The kit of Claim 18, wherein the disorder related to DYRK1 activity is Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune disease, an inflammatory disorder (e.g., airway inflammation), or cancer (e.g., glioblastoma).

20. The kit of Claim 18, further comprising one or more agents for treating Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune disease, an inflammatory disorder (e.g., airway inflammation), or cancer (e.g., glioblastoma).

21. A method for inhibiting DYRK1A related activity in a subject, comprising administering to the subject a compound of Claim 1.

22. The method of Claim 21 , wherein administration of the compound results in inhibition of one or more DYRK1 A related activities in the subject:

DYRKIA related PI3K/Akt signaling;

DYRKIA related tau phosphorylation;

DYRKIA related NFAT phosphorylation;

DYRKIA related ASK1/JNK1 pathway activation;

DYRKIA related p53 phosphorylation;

DYRKIA related Amph 1 phosphorylation;

103 DYRK1A related Dynamin 1 phosphorylation;

DYRK1A related Synaptojanin phosphorylation;

DYRK1 A related presenilin 1 (the catalytic sub-unit of γ-secretase) activity;

DYRK1A related Amyloid precursor protein phosphorylation; and

DYRK1A related SIRT1 activation.

23. The method of Claim 21 , wherein the subject is human subject suffering from or at risk for developing a disorder related to DYRK1 A activity.

24. The method of Claim 23, wherein the disorder related to DYRK1A activity is

Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune disease, an inflammatory disorder (e.g., airway inflammation), or cancer (e.g., glioblastoma).

104